Shire to buy rare disease specialist Dyax for $5.9 billion
The offer price of $37.30 per share represents a 35.5 percent premium to Dyax's closing stock price on Friday.
Dyax shareholders will also get a non-tradable contingent value right potentially worth $4.00 a share, or an additional $646 million, if Dyax's DX-2930 drug, which could reach the market in 2018, is approved for hereditary angioedema (HAE).
Shire believes DX-2930 has potential to expand the number of HAE patients treated and achieve annual worldwide sales of up to $2 billion, while enjoying exclusivity beyond 2030. ■